Novimmune

Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases. The company was founded in 1998.

Novimmune has six publicly disclosed drug in their pipeline:

NI-0101, an anti-TLR4 antibody being developed in partnership with Genentech. A phase I clinical trial was completed in 2014 and phase II trials are expected to begin in early 2017.
NI-0401, an anti-CD3ε antibody being developed in partnership with Tiziana Life Sciences. Phase II trials in patients with Crohn's disease and transplant rejection finished in 2008 and 2009, respectively.
NI-0501, an anti-IFNγ antibody, is in development for hemophagocytic lymphohistiocytosis. A phase II/III trial began in 2013 and is ongoing. The FDA awarded breakthrough status to the drug in 2016.
NI-1401, an anti-IL17 drug being developed in partnership with Genentech for inflammatory and auto-immune diseases.
NI-1701, an anti-CD47, anti-CD19 bispecific antibody in development for treatment of B-cell hematological cancers.
NI-1801, an anti-CD47, anti-mesothelin bispecific antibody in the preclinical phase of development for treatment of solid tumors.

No drugs have been approved yet.

References

↑ "Novimmune's NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With Primary Hemophagocytic Lymphohistiocytosis (HLH) - FierceBiotech". www.fiercebiotech.com.
↑ "Novimmune SA: Private Company Information - Bloomberg". www.bloomberg.com.
↑ "First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers - Full Text View - ClinicalTrials.gov".
↑ "Pipeline - NI-0101 anti-TLR4". www.novimmune.com.
↑ "NI-0401 in Patients With Acute Renal Allograft Rejection - Full Text View - ClinicalTrials.gov".
↑ "Pipeline | NI-0501 anti-IFNγ". Archived from the original on 2017-01-13. Retrieved 2017-01-11.
↑ "Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody - Full Text View - ClinicalTrials.gov".
↑ "A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis - Full Text View - ClinicalTrials.gov".
↑ "Emapalumab - NovImmune - AdisInsight". adisinsight.springer.com.
↑ "Pipeline - NI-1401 anti-IL17". www.novimmune.com.
↑ "Pipeline - NI-1801 anti-CD47/Mesothelin". www.novimmune.com.

[1] "Novimmune's NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With Primary Hemophagocytic Lymphohistiocytosis (HLH) - FierceBiotech". www.fiercebiotech.com.

[2] "Novimmune SA: Private Company Information - Bloomberg". www.bloomberg.com.

[3] "First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers - Full Text View - ClinicalTrials.gov".

[4] "Pipeline - NI-0101 anti-TLR4". www.novimmune.com.

[5] "NI-0401 in Patients With Acute Renal Allograft Rejection - Full Text View - ClinicalTrials.gov".

[6] "Pipeline | NI-0501 anti-IFNγ". Archived from the original on 2017-01-13. Retrieved 2017-01-11.

[7] "Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody - Full Text View - ClinicalTrials.gov".

[8] "A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis - Full Text View - ClinicalTrials.gov".

[9] "Emapalumab - NovImmune - AdisInsight". adisinsight.springer.com.

[10] "Pipeline - NI-1401 anti-IL17". www.novimmune.com.

[11] "Pipeline - NI-1801 anti-CD47/Mesothelin". www.novimmune.com.